QuickView for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=2900716895C7B22D189A0773046E2D52;jsessionid=CA952A44FE01AE77031BFB7DBD162FCB;jsessionid=E9EBC58B6D7090235D1BBF1D54205DD6;jsessionid=C1A421CEF5491E009D11E57AFFDD5094 (gene)

1. CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for …
2. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
3. Antifibrotic Soluble Thy-1 Correlates with Renal Dysfunction in Chronic Kidney Disease.
4. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leu…
5. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.

There were no clinical trials for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=2900716895C7B22D189A0773046E2D52;jsessionid=CA952A44FE01AE77031BFB7DBD162FCB;jsessionid=E9EBC58B6D7090235D1BBF1D54205DD6;jsessionid=C1A421CEF5491E009D11E57AFFDD5094